REGENXBIO Inc. Cash and Cash Equivalents, Period Increase (Decrease)
REGENXBIO Inc. (RGNX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $21.82 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-06.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-06
- REGENXBIO Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$13.23M.
- REGENXBIO Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $2.23M.
- REGENXBIO Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$24.40M.
- REGENXBIO Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $57.20M.
- REGENXBIO Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $21.82M.
- REGENXBIO Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$29.28M, a 155.24% decline from fiscal 2015.
- REGENXBIO Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $52.99M, a 2649650.00% increase from fiscal 2014.
- REGENXBIO Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $2.00K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$13.23M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | -$10.99M derived: sum of 2 quarters · filed 2018-03-06 | -$35.39M derived: sum of 3 quarters · filed 2018-03-06 | $21.82M 10-K · filed 2018-03-06 |
| 2017-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$22.16M derived: sum of 2 quarters · filed 2017-11-08 | $35.04M 10-Q · filed 2017-11-08 | $31.78M derived: sum of 4 quarters · filed 2018-03-06 |
| 2017-06-30 | -$24.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $32.81M 10-Q · filed 2017-08-08 | $29.54M derived: sum of 3 quarters · filed 2018-03-06 | $27.57M derived: sum of 4 quarters · filed 2018-03-06 |
| 2017-03-31 | $57.20M 10-Q · filed 2017-05-09 | $53.94M derived: sum of 2 quarters · filed 2018-03-06 | $51.96M derived: sum of 3 quarters · filed 2018-03-06 | $46.53M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-12-31 | -$3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | -$5.24M derived: sum of 2 quarters · filed 2018-03-06 | -$10.67M derived: sum of 3 quarters · filed 2018-03-06 | -$29.28M 10-K · filed 2018-03-06 |
| 2016-09-30 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$7.40M derived: sum of 2 quarters · filed 2017-11-08 | -$26.01M 10-Q · filed 2017-11-08 | -$177.22M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | -$5.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$24.03M 10-Q · filed 2017-08-08 | -$175.24M derived: sum of 3 quarters · filed 2018-03-06 | -$55.13M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-03-31 | -$18.61M 10-Q · filed 2017-05-09 | -$169.81M derived: sum of 2 quarters · filed 2018-03-06 | -$49.70M derived: sum of 3 quarters · filed 2018-03-06 | $10.14M derived: sum of 4 quarters · filed 2018-03-06 |
| 2015-12-31 | -$151.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | -$31.10M derived: sum of 2 quarters · filed 2018-03-06 | $28.75M derived: sum of 3 quarters · filed 2018-03-06 | $52.99M 10-K · filed 2018-03-06 |
| 2015-09-30 | $120.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $179.96M derived: sum of 2 quarters · filed 2016-11-09 | $204.20M 10-Q · filed 2016-11-09 | $204.34M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-06-30 | $59.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $84.09M 10-Q · filed 2016-08-09 | $84.23M derived: sum of 3 quarters · filed 2017-03-07 | |
| 2015-03-31 | $24.25M 10-Q · filed 2016-05-05 | $24.39M derived: sum of 2 quarters · filed 2017-03-07 | ||
| 2014-12-31 | $139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $2.00K 10-K · filed 2017-03-07 | ||
| 2014-09-30 | -$137.00K 10-Q · filed 2015-11-05 | |||
| 2013-12-31 | -$1.05M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |